Busra Gurpinar Tosun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Busra Gurpinar Tosun has a total of 139 co-authors. Here are the top co-authors by number of shared publications:
- Tulay Guran
Department of Pediatric Endocrinology and Diabetes, Faculty of Medicine, Marmara University , 34854, Istanbul
16 shared publications - Abdullah Bereket
Department of Pediatric Endocrinology, Marmara University Faculty of Medicine, İstanbul, Türkiye
12 shared publications - Serap Turan
Marmara University School of Medicine Department of Pediatric Endocrinology, Istanbul, Turkey
9 shared publications - Didem Helvacioglu
Department of Pediatric Endocrinology, Marmara University Faculty of Medicine, İstanbul, Türkiye
6 shared publications - Belma Haliloglu
Department of Paediatric Endocrinology Marmara University Faculty of Medicine Istanbul Türkiye
3 shared publications Ozge Yapici
Department of Radiology, Marmara University School of Medicine , Istanbul 34854
3 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by Aydin Pediatric Society in Trends in Pediatrics
- Vol. 7 (3) , 219-228
First-year efficacy of 3.75 mg versus 11.25 mg depot leuprolide acetate and predictors of biochemical non-suppression in girls with central precocious puberty
Objective: To compare first-year biochemical and auxological outcomes of monthly 3.75 mg and 3-monthly 11.25 mg depot leuprolide acetate (dLA) treatment in girls with central precocious puberty (CPP) and to evaluate factors associated with biochemical non-suppression and first-year growth velocity. Methods: This single-center prospective quasi-randomized comparative study included 87 girls with CPP treated with dLA for 12 months. Patients received either monthly 3.75 mg (n=46) or 3-monthly 11.25 mg dLA treatment (n=41). Auxological parameters, gonadotropin-releasing hormone (GnRH)-stimulated luteinizing hormone (LH) responses, and LH levels measured 40 minutes after dLA injection (40-minute post-dLA LH) were evaluated. Biochemical non-suppression was defined as a year-one 40-minute post-dLA LH level >3.07 IU/L. Logistic regression was used to identify predictors of biochemical non-suppression, and linear regression was performed to determine factors associated with first-year annual growth velocity. Results: One year after initiation of treatment, there was no difference in annual growth velocity (5.73 ± 1.01 vs 5.81 ± 0.92 cm/year, p=0.956), bone age, Δbone age, and other auxological and pelvic ultrasonographic parameters between treatment groups. Year-one biochemical suppression was achieved in 33/46 patients (71.7%) in the 3.75 mg group and 33/41 patients (80.5%) in the 11.25 mg group, with no significant between-group difference (p=0.450). Biochemical non-suppression was associated with higher annual growth velocity and higher pretreatment GnRH-stimulated peak LH; in logistic regression analysis, pretreatment GnRH-stimulated peak LH was the only independent predictor of biochemical non-suppression (adjusted OR 1.04, 95% CI 1.01–1.07, p=0.012). First-year annual growth velocity correlated with 6-month GnRH-stimulated peak LH (r=0.320, p=0.003), 6-month 40-minute post-dLA LH (r=0.339, p=0.001), year-one basal LH (r=0.314, p=0.003), and year-one 40-minute post-dLA LH (r=0.517, p<0.001). In multivariable analysis, year-one 40-minute post-dLA LH remained independently associated with annual growth velocity (B=0.39, 95% CI 0.26–0.52, p<0.001), whereas other parameters did not. Conclusions: Monthly 3.75 mg and 3-monthly 11.25 mg depot leuprolide acetate provided comparable first-year auxological outcomes. Higher pretreatment GnRH-stimulated peak LH predicted biochemical non-suppression, whereas year-one 40-minute post-dLA LH level was independently associated with first-year growth velocity, suggesting that it may represent a more robust parameter for monitoring residual pubertal activity during treatment.
- 30 September 2026
- Published by Aydin Pediatric Society in Trends in Pediatrics
- Vol. 7 (3) , 219-228
Open AccessFirst-year efficacy of 3.75 mg versus 11.25 mg depot leuprolide acetate and predictors of biochemical non-suppression in girls with central precocious puberty
Objective: To compare first-year biochemical and auxological outcomes of monthly 3.75 mg and 3-monthly 11.25 mg depot leuprolide acetate (dLA) treatment in girls with central precocious puberty (CPP) and to evaluate factors associated with biochemical non-suppression and first-year growth velocity. Methods: This single-center prospective quasi-randomized comparative study included 87 girls with CPP treated with dLA for 12 months. Patients received either monthly 3.75 mg (n=46) or 3-monthly 11.25 mg dLA treatment (n=41). Auxological parameters, gonadotropin-releasing hormone (GnRH)-stimulated luteinizing hormone (LH) responses, and LH levels measured 40 minutes after dLA injection (40-minute post-dLA LH) were evaluated. Biochemical non-suppression was defined as a year-one 40-minute post-dLA LH level >3.07 IU/L. Logistic regression was used to identify predictors of biochemical non-suppression, and linear regression was performed to determine factors associated with first-year annual growth velocity. Results: One year after initiation of treatment, there was no difference in annual growth velocity (5.73 ± 1.01 vs 5.81 ± 0.92 cm/year, p=0.956), bone age, Δbone age, and other auxological and pelvic ultrasonographic parameters between treatment groups. Year-one biochemical suppression was achieved in 33/46 patients (71.7%) in the 3.75 mg group and 33/41 patients (80.5%) in the 11.25 mg group, with no significant between-group difference (p=0.450). Biochemical non-suppression was associated with higher annual growth velocity and higher pretreatment GnRH-stimulated peak LH; in logistic regression analysis, pretreatment GnRH-stimulated peak LH was the only independent predictor of biochemical non-suppression (adjusted OR 1.04, 95% CI 1.01–1.07, p=0.012). First-year annual growth velocity correlated with 6-month GnRH-stimulated peak LH (r=0.320, p=0.003), 6-month 40-minute post-dLA LH (r=0.339, p=0.001), year-one basal LH (r=0.314, p=0.003), and year-one 40-minute post-dLA LH (r=0.517, p<0.001). In multivariable analysis, year-one 40-minute post-dLA LH remained independently associated with annual growth velocity (B=0.39, 95% CI 0.26–0.52, p<0.001), whereas other parameters did not. Conclusions: Monthly 3.75 mg and 3-monthly 11.25 mg depot leuprolide acetate provided comparable first-year auxological outcomes. Higher pretreatment GnRH-stimulated peak LH predicted biochemical non-suppression, whereas year-one 40-minute post-dLA LH level was independently associated with first-year growth velocity, suggesting that it may represent a more robust parameter for monitoring residual pubertal activity during treatment.
- Open Access
- 26 June 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (10) , 2737-2744
Machine Learning Algorithms to Accelerate Etiological Diagnosis of Congenital Disorders of Adrenal Steroidogenesis
Background: Early and accurate etiological diagnosis of congenital disorders of adrenal steroidogenesis (CDAS) is critical as timely targeted management can prevent life-threatening complications and improve long-term outcomes. Objective: To develop and validate a machine learning–assisted decision tree model for classifying CDAS using plasma steroid hormone profiles quantified by liquid chromatography–mass spectrometry (LC–MS/MS). Methods: A development cohort of 1027 participants (325 genetically confirmed CDAS patients representing eight subtypes/702 controls) was used for model construction. The Light Gradient Boosting Machine algorithm identified key discriminatory steroid hormones, which were integrated into an optimized decision-tree classifier. Internal performance was assessed through five-fold cross-validation. The performance of the model was further evaluated using a validation cohort comprising 507 independent LC–MS/MS steroid profiles. Additional analyses included Shapley additive explanations (SHAP), confusion matrix visualization, Principal Component Analysis (PCA), and Uniform Manifold Approximation and Projection (UMAP). Results: In the development cohort, the model achieved a mean overall accuracy of 97.1%, sensitivity of 99.5%, and specificity of 93.7%, with a macro-AUC (area under curve) of 0.97. Subtype-level accuracy exceeded 98% for most major CDAS subtypes. In the validation cohort, overall accuracy was 98.9%, sensitivity 93.6%, specificity 99.8%. Feature importance analysis and SHAP identified 11-deoxycortisol, 17-hydroxyprogesterone, 21-deoxycortisol, and corticosterone as the strongest discriminators. PCA and UMAP revealed distinct clustering of CDAS subtypes, confirming the biological coherence of model predictions. Conclusion: Machine learning–assisted steroid profiling provides an accurate and highly interpretable diagnostic approach for CDAS, with potential for integration into pediatric endocrine diagnostics and decision-support systems.
- 26 June 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (10) , 2737-2744
Open AccessMachine Learning Algorithms to Accelerate Etiological Diagnosis of Congenital Disorders of Adrenal Steroidogenesis
Background: Early and accurate etiological diagnosis of congenital disorders of adrenal steroidogenesis (CDAS) is critical as timely targeted management can prevent life-threatening complications and improve long-term outcomes. Objective: To develop and validate a machine learning–assisted decision tree model for classifying CDAS using plasma steroid hormone profiles quantified by liquid chromatography–mass spectrometry (LC–MS/MS). Methods: A development cohort of 1027 participants (325 genetically confirmed CDAS patients representing eight subtypes/702 controls) was used for model construction. The Light Gradient Boosting Machine algorithm identified key discriminatory steroid hormones, which were integrated into an optimized decision-tree classifier. Internal performance was assessed through five-fold cross-validation. The performance of the model was further evaluated using a validation cohort comprising 507 independent LC–MS/MS steroid profiles. Additional analyses included Shapley additive explanations (SHAP), confusion matrix visualization, Principal Component Analysis (PCA), and Uniform Manifold Approximation and Projection (UMAP). Results: In the development cohort, the model achieved a mean overall accuracy of 97.1%, sensitivity of 99.5%, and specificity of 93.7%, with a macro-AUC (area under curve) of 0.97. Subtype-level accuracy exceeded 98% for most major CDAS subtypes. In the validation cohort, overall accuracy was 98.9%, sensitivity 93.6%, specificity 99.8%. Feature importance analysis and SHAP identified 11-deoxycortisol, 17-hydroxyprogesterone, 21-deoxycortisol, and corticosterone as the strongest discriminators. PCA and UMAP revealed distinct clustering of CDAS subtypes, confirming the biological coherence of model predictions. Conclusion: Machine learning–assisted steroid profiling provides an accurate and highly interpretable diagnostic approach for CDAS, with potential for integration into pediatric endocrine diagnostics and decision-support systems.
- Open Access
- 26 May 2026
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 49 (9) , 2375-2383
Utility of a 40-minute LH level after depot leuprolide for diagnosis and treatment monitoring in girls with CPP
Purpose: Gonadotropin-releasing-hormone (GnRH) stimulation test is used for assessment of gonadotropic activation in patients with central precocious puberty (CPP). However, it is invasive and GnRH preparation is not available in all countries. Depot-leuprolide acetate (dLA), used for the treatment of CPP, stimulates gonadotropins briefly before suppressing them. This study aimed to evaluate the utility of luteinizing hormone (LH) level measured 40-minutes after dLA injection for assessing gonadotropic activation compared to GnRH stimulation test. Methods: In this prospective study, girls with idiopathic CPP were randomized to receive dLA 3.75 mg/4 weeks IM, 11.25 mg/12 weeks SC or 11.25 mg/12 weeks IM. A standard GnRH test was performed before (baseline) and after 6 months of treatment. Forty minutes after the first dLA injection, LH and follicle-stimulating hormone (FSH) levels were measured, and the same measurements were repeated after 6 months of treatment. Results: The study recruited 132 girls. Peak LH on the GnRH test did not differ from the 40-minute-post-dLA LH levels [11.0(6.8–17.1) vs. 9.4(5.8–16.6); p = 0.06]. There were no significant differences between the treatment groups. Using the GnRH test peak of LH ≥ 5 IU/L as the gold-standard, ROC analysis identified the optimal cut-off of post-dLA injection LH ≥ 5.4 IU/L on initial measurement (sensitivity = 86%, specificity = 90% and AUC = 0.91). At 6 months, peak LH levels in treatment groups were similarly suppressed (2.1 ± 1.6, 2.5 ± 1.8, 2.2 ± 0.9; p = 0.2011). Furthermore, post- dLA LH cut-off of < 3.07 IU/L yielded an AUC = 0.83, sensitivity = 80.8% and specificity = 75.5%. Conclusion: The 40-minute post-dLA LH provided clinically useful information concerning gonadotropic activity for both diagnosis and treatment monitoring and may provide a practical and clinically informative alternative in selected settings, particularly when standard GnRH testing is not readily available.
- 26 May 2026
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 49 (9) , 2375-2383
Open AccessUtility of a 40-minute LH level after depot leuprolide for diagnosis and treatment monitoring in girls with CPP
Purpose: Gonadotropin-releasing-hormone (GnRH) stimulation test is used for assessment of gonadotropic activation in patients with central precocious puberty (CPP). However, it is invasive and GnRH preparation is not available in all countries. Depot-leuprolide acetate (dLA), used for the treatment of CPP, stimulates gonadotropins briefly before suppressing them. This study aimed to evaluate the utility of luteinizing hormone (LH) level measured 40-minutes after dLA injection for assessing gonadotropic activation compared to GnRH stimulation test. Methods: In this prospective study, girls with idiopathic CPP were randomized to receive dLA 3.75 mg/4 weeks IM, 11.25 mg/12 weeks SC or 11.25 mg/12 weeks IM. A standard GnRH test was performed before (baseline) and after 6 months of treatment. Forty minutes after the first dLA injection, LH and follicle-stimulating hormone (FSH) levels were measured, and the same measurements were repeated after 6 months of treatment. Results: The study recruited 132 girls. Peak LH on the GnRH test did not differ from the 40-minute-post-dLA LH levels [11.0(6.8–17.1) vs. 9.4(5.8–16.6); p = 0.06]. There were no significant differences between the treatment groups. Using the GnRH test peak of LH ≥ 5 IU/L as the gold-standard, ROC analysis identified the optimal cut-off of post-dLA injection LH ≥ 5.4 IU/L on initial measurement (sensitivity = 86%, specificity = 90% and AUC = 0.91). At 6 months, peak LH levels in treatment groups were similarly suppressed (2.1 ± 1.6, 2.5 ± 1.8, 2.2 ± 0.9; p = 0.2011). Furthermore, post- dLA LH cut-off of < 3.07 IU/L yielded an AUC = 0.83, sensitivity = 80.8% and specificity = 75.5%. Conclusion: The 40-minute post-dLA LH provided clinically useful information concerning gonadotropic activity for both diagnosis and treatment monitoring and may provide a practical and clinically informative alternative in selected settings, particularly when standard GnRH testing is not readily available.
- 4 February 2026
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 194 (2) , 225-232
Adrenal androgens as predictors of growth characteristics in premature pubarche
Background: Premature pubarche (PP) is characterized by the early onset of pubic or axillary hair, body odor, or mild acne, most commonly reflected by elevated plasma dehydroepiandrosterone-sulfate (DHEA-S) concentrations. However, recent evidence suggests that 11-oxygenated adrenal androgens [11β-hydroxyandrostenedione (11OHA4), 11β-hydroxytestosterone (11OHT)] may better represent true androgenic activity. Aim: This study aims to evaluate the predictive value of adrenal androgens in determining growth characteristics among girls with PP. Subjects and Methods: A prospective study was conducted to evaluate anthropometric and clinical features and to quantify plasma adrenal androgens—including DHEA, DHEA-S, androstenedione (A4), androsterone, 11OHA4, and 11OHT—using liquid chromatography-mass spectrometry in 53 girls with isolated PP at presentation and during follow-up. Thirty-six age-matched girls without PP served as the control group. Results: The height, body mass index-standard deviation score (SDS), DHEA, DHEA-S, A4, androsterone, and 17OH-pregnenolone concentrations were higher (P < .0001), whereas no difference in 11OHA4 and 11OHT concentrations was observed in the PP group compared with controls. There was no correlation of adrenal androgen concentrations with height, corrected height, and growth velocity at baseline or during follow-up of 2.7 years. Corrected height SDS was positively correlated with baseline corrected height SDS (r = .63, P < .0001), baseline bone age (BA)/chronological age ratio (r = .31, P = .02), and baseline BA SDS (r = .32, P = .01) but not with hormone concentrations. Conclusion: Isolated idiopathic PP appears to be a benign variant of normal development. In this setting, adrenal androgen concentrations are not associated with adverse linear growth outcomes and are unlikely to influence clinical management, supporting a conservative approach after exclusion of pathological causes.
- 4 February 2026
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 194 (2) , 225-232
Adrenal androgens as predictors of growth characteristics in premature pubarche
Background: Premature pubarche (PP) is characterized by the early onset of pubic or axillary hair, body odor, or mild acne, most commonly reflected by elevated plasma dehydroepiandrosterone-sulfate (DHEA-S) concentrations. However, recent evidence suggests that 11-oxygenated adrenal androgens [11β-hydroxyandrostenedione (11OHA4), 11β-hydroxytestosterone (11OHT)] may better represent true androgenic activity. Aim: This study aims to evaluate the predictive value of adrenal androgens in determining growth characteristics among girls with PP. Subjects and Methods: A prospective study was conducted to evaluate anthropometric and clinical features and to quantify plasma adrenal androgens—including DHEA, DHEA-S, androstenedione (A4), androsterone, 11OHA4, and 11OHT—using liquid chromatography-mass spectrometry in 53 girls with isolated PP at presentation and during follow-up. Thirty-six age-matched girls without PP served as the control group. Results: The height, body mass index-standard deviation score (SDS), DHEA, DHEA-S, A4, androsterone, and 17OH-pregnenolone concentrations were higher (P < .0001), whereas no difference in 11OHA4 and 11OHT concentrations was observed in the PP group compared with controls. There was no correlation of adrenal androgen concentrations with height, corrected height, and growth velocity at baseline or during follow-up of 2.7 years. Corrected height SDS was positively correlated with baseline corrected height SDS (r = .63, P < .0001), baseline bone age (BA)/chronological age ratio (r = .31, P = .02), and baseline BA SDS (r = .32, P = .01) but not with hormone concentrations. Conclusion: Isolated idiopathic PP appears to be a benign variant of normal development. In this setting, adrenal androgen concentrations are not associated with adverse linear growth outcomes and are unlikely to influence clinical management, supporting a conservative approach after exclusion of pathological causes.
- Open Access
- 15 October 2025
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 18 (2) , 233-242
Isolated Hypoglyceamia in Children with Cystic Fibrosis: Role of Pancreatic Insufficiency and Glucagon Response
Isolated Hypoglyceamia in Children with Cystic Fibrosis: Role of Pancreatic Insufficiency and Glucagon Response - Journal of Clinical Research in Pediatric Endocrinology
- 15 October 2025
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 18 (2) , 233-242
Open AccessIsolated Hypoglyceamia in Children with Cystic Fibrosis: Role of Pancreatic Insufficiency and Glucagon Response
Isolated Hypoglyceamia in Children with Cystic Fibrosis: Role of Pancreatic Insufficiency and Glucagon Response - Journal of Clinical Research in Pediatric Endocrinology
- 21 August 2025
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 193 (3) , L17
Response to the letter by Schmitt et al.
- 21 August 2025
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 193 (3) , L17
Response to the letter by Schmitt et al.
- Open Access
- 23 May 2025
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 17 (4) , 488-493
The First-year Outcomes of the Nationwide Neonatal CAH Screening in Türkiye: High Rate of False Positives for 21-hydroxylase Deficiency and a Higher Detection Rate of Non-classical Cases
The First-year Outcomes of the Nationwide Neonatal CAH Screening in Türkiye: High Rate of False Positives for 21-hydroxylase Deficiency and a Higher Detection Rate of Non-classical Cases - Journal of Clinical Research in Pediatric Endocrinology
- 23 May 2025
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 17 (4) , 488-493
Open AccessThe First-year Outcomes of the Nationwide Neonatal CAH Screening in Türkiye: High Rate of False Positives for 21-hydroxylase Deficiency and a Higher Detection Rate of Non-classical Cases
The First-year Outcomes of the Nationwide Neonatal CAH Screening in Türkiye: High Rate of False Positives for 21-hydroxylase Deficiency and a Higher Detection Rate of Non-classical Cases - Journal of Clinical Research in Pediatric Endocrinology
- 30 April 2025
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 192 (5) , K38-K43
Primary adrenal insufficiency caused by pseudo-neonatal adrenoleukodystrophy associated with biallelic ACOX1 mutations
Background: Peroxisomal fatty acyl-CoA oxidase 1, encoded by ACOX1, initiates and limits the rate of beta-oxidation of very long-chain fatty acids (VLCFA). Biallelic ACOX1 mutations cause pseudo-neonatal adrenoleukodystrophy (PNALD). Primary adrenal insufficiency (PAI) has not been clearly characterized in the 34 PNALD patients reported to date. Objective: Characterizing PAI in a patient and her cousin with PNALD. Methods: Clinical data were recorded, and molecular etiologies were investigated using next-generation sequencing panels and 750K microarray. Plasma steroids and VLCFAs were measured via mass spectrometry. Results: A 1.5-year-old female patient was evaluated for PAI due to hyperpigmentation, hypoglycemia, hyponatremia and hyperkalemia. She had a history of severe neonatal-onset hypotonia, seizures, psychomotor/developmental delay, and neurological regression. Molecular studies revealed a homozygous deletion encompassing exons 13 and 14 of the ACOX1 gene. Biochemical analysis revealed accumulation of saturated VLCFA. Cranial magnetic resonance imaging showed T2 high-intensity areas in bilateral centrum semiovale, basal ganglia, brainstem and cerebellar white matter. High plasma ACTH, low cortisol and steroid precursors along with high plasma renin activity were compatible with a PAI other than congenital adrenal hyperplasia (non-CAH). Abdominal computerized tomography demonstrated bilateral adrenal atrophy. The cousin of the patient with PNALD developed non-CAH PAI at 7 months of age. Conclusion: Adrenal insufficiency should be considered in the phenotypic spectrum of peroxisomal disorders. Fatty acyl-CoA oxidase 1 deficiency may emerge as a peroxisomal etiology of non-CAH PAI.
- 30 April 2025
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 192 (5) , K38-K43
Primary adrenal insufficiency caused by pseudo-neonatal adrenoleukodystrophy associated with biallelic ACOX1 mutations
Background: Peroxisomal fatty acyl-CoA oxidase 1, encoded by ACOX1, initiates and limits the rate of beta-oxidation of very long-chain fatty acids (VLCFA). Biallelic ACOX1 mutations cause pseudo-neonatal adrenoleukodystrophy (PNALD). Primary adrenal insufficiency (PAI) has not been clearly characterized in the 34 PNALD patients reported to date. Objective: Characterizing PAI in a patient and her cousin with PNALD. Methods: Clinical data were recorded, and molecular etiologies were investigated using next-generation sequencing panels and 750K microarray. Plasma steroids and VLCFAs were measured via mass spectrometry. Results: A 1.5-year-old female patient was evaluated for PAI due to hyperpigmentation, hypoglycemia, hyponatremia and hyperkalemia. She had a history of severe neonatal-onset hypotonia, seizures, psychomotor/developmental delay, and neurological regression. Molecular studies revealed a homozygous deletion encompassing exons 13 and 14 of the ACOX1 gene. Biochemical analysis revealed accumulation of saturated VLCFA. Cranial magnetic resonance imaging showed T2 high-intensity areas in bilateral centrum semiovale, basal ganglia, brainstem and cerebellar white matter. High plasma ACTH, low cortisol and steroid precursors along with high plasma renin activity were compatible with a PAI other than congenital adrenal hyperplasia (non-CAH). Abdominal computerized tomography demonstrated bilateral adrenal atrophy. The cousin of the patient with PNALD developed non-CAH PAI at 7 months of age. Conclusion: Adrenal insufficiency should be considered in the phenotypic spectrum of peroxisomal disorders. Fatty acyl-CoA oxidase 1 deficiency may emerge as a peroxisomal etiology of non-CAH PAI.
- 29 April 2025
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 192 (5) , K31-K37
Primary adrenal insufficiency in patients with CPOX gene mutations
Background: Harderoporphyria arises from biallelic CPOX gene mutations, leading to coproporphyrinogen oxidase deficiency in the inner mitochondrial membrane. The impact of CPOX gene mutations on adrenal function remains poorly understood. Objective: Characterizing primary adrenal insufficiency (PAI) in 2 siblings with harderoporphyria. Methods: Clinical data were recorded, and genetic analysis was performed by whole genome sequencing (WGS). Plasma steroids and urinary porphyrins were measured by liquid chromatography-mass spectrometry and high-performance liquid chromatography, respectively. Mitochondrial function was assessed using the mitochondrial membrane potential (MMP) assay in peripheral blood mononuclear cells. Results: Patients were diagnosed with PAI at 4.5 years (P1, 46,XY) and 7 months (P2, 46,XX). P1 had atypical genitalia and developed primary gonadal insufficiency and non-immune diabetes at ages 6 and 10, respectively. Both patients had a history of microcytic anaemia, haemolysis, cholestasis, hepatosplenomegaly in early infancy, hyperpigmentation, abdominal pain, nystagmus, optic atrophy, and mild lactic acidosis in early childhood. WGS revealed a homozygous c.83_85del, p.S28* variant in CPOX. Oxidative damage to mitochondria was shown by decreased MMP in patients compared with controls (P < .0001). Hormonal assessment indicated severe PAI, suggestive of combined CYP11A1 and CYP11B1 deficiency. Conclusions: CPOX gene mutations cause a mixed model of PAI, affecting mitochondrial steroidogenic enzymes. Clinical manifestations of harderoporphyria may overlap with PAI signs.
- 29 April 2025
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 192 (5) , K31-K37
Primary adrenal insufficiency in patients with CPOX gene mutations
Background: Harderoporphyria arises from biallelic CPOX gene mutations, leading to coproporphyrinogen oxidase deficiency in the inner mitochondrial membrane. The impact of CPOX gene mutations on adrenal function remains poorly understood. Objective: Characterizing primary adrenal insufficiency (PAI) in 2 siblings with harderoporphyria. Methods: Clinical data were recorded, and genetic analysis was performed by whole genome sequencing (WGS). Plasma steroids and urinary porphyrins were measured by liquid chromatography-mass spectrometry and high-performance liquid chromatography, respectively. Mitochondrial function was assessed using the mitochondrial membrane potential (MMP) assay in peripheral blood mononuclear cells. Results: Patients were diagnosed with PAI at 4.5 years (P1, 46,XY) and 7 months (P2, 46,XX). P1 had atypical genitalia and developed primary gonadal insufficiency and non-immune diabetes at ages 6 and 10, respectively. Both patients had a history of microcytic anaemia, haemolysis, cholestasis, hepatosplenomegaly in early infancy, hyperpigmentation, abdominal pain, nystagmus, optic atrophy, and mild lactic acidosis in early childhood. WGS revealed a homozygous c.83_85del, p.S28* variant in CPOX. Oxidative damage to mitochondria was shown by decreased MMP in patients compared with controls (P < .0001). Hormonal assessment indicated severe PAI, suggestive of combined CYP11A1 and CYP11B1 deficiency. Conclusions: CPOX gene mutations cause a mixed model of PAI, affecting mitochondrial steroidogenic enzymes. Clinical manifestations of harderoporphyria may overlap with PAI signs.
- 3 March 2025
- Published by S. Karger AG in Hormone Research in Paediatrics
- Vol. 99 (5) , 1-12
Optimal Low Dose Synacthen Stimulation Test Sampling Time for Diagnosis of Adrenal Insufficiency Using Monoclonal Antibody Immunoassay
Context: The low-dose synacthen stimulation test (LDSST) evaluates hypothalamo-pituitary-adrenal axis function. However, studies on the correlation between morning basal and stimulated cortisol concentrations using specific monoclonal antibody immunoassays during LDSST are limited. Objective: To determine the best time points and sampling approach for cortisol measurement using mAb immunoassay in children during LDSST. Design and Setting: Morning basal and stimulated serum cortisol measurements in the LDSST were prospectively analysed in 132 children (61 girls) with clinical suspicion of adrenal insufficiency (AI). Methods: Serum cortisol concentrations were assessed at 0, 30, 40, and 60th minutes during LDSST using mAb immunoassay. Simultaneously, morning basal cortisol levels in 119 patients were measured with both mAb immunoassay and liquid chromatography-mass spectrometry. Adrenal insufficiency (AI) was defined by a peak plasma cortisol concentration below 18 μg/dL (500 nmol/L). Results: Adrenal insufficiency (AI) was excluded in 80.3% (n=106) of patients. The 40th minute showed the highest specificity (89.1%) for predicting LDSST outcomes with a single cortisol measurement. For two time-point measurements, the 40th and 60th minutes were significantly more sensitive than other possibilities (p<0.001). A morning basal cortisol level below 6.5 μg/dL was identified as predictive of a failed LDSST result. Conclusions: In LDSST, measurement of plasma cortisol at 40th and 60th minutes reduces the risk of false positivity. Single sampling at 40th minute yielded fewer false negatives than sampling at 30th or 60th minute.
- 3 March 2025
- Published by S. Karger AG in Hormone Research in Paediatrics
- Vol. 99 (5) , 1-12
Optimal Low Dose Synacthen Stimulation Test Sampling Time for Diagnosis of Adrenal Insufficiency Using Monoclonal Antibody Immunoassay
Context: The low-dose synacthen stimulation test (LDSST) evaluates hypothalamo-pituitary-adrenal axis function. However, studies on the correlation between morning basal and stimulated cortisol concentrations using specific monoclonal antibody immunoassays during LDSST are limited. Objective: To determine the best time points and sampling approach for cortisol measurement using mAb immunoassay in children during LDSST. Design and Setting: Morning basal and stimulated serum cortisol measurements in the LDSST were prospectively analysed in 132 children (61 girls) with clinical suspicion of adrenal insufficiency (AI). Methods: Serum cortisol concentrations were assessed at 0, 30, 40, and 60th minutes during LDSST using mAb immunoassay. Simultaneously, morning basal cortisol levels in 119 patients were measured with both mAb immunoassay and liquid chromatography-mass spectrometry. Adrenal insufficiency (AI) was defined by a peak plasma cortisol concentration below 18 μg/dL (500 nmol/L). Results: Adrenal insufficiency (AI) was excluded in 80.3% (n=106) of patients. The 40th minute showed the highest specificity (89.1%) for predicting LDSST outcomes with a single cortisol measurement. For two time-point measurements, the 40th and 60th minutes were significantly more sensitive than other possibilities (p<0.001). A morning basal cortisol level below 6.5 μg/dL was identified as predictive of a failed LDSST result. Conclusions: In LDSST, measurement of plasma cortisol at 40th and 60th minutes reduces the risk of false positivity. Single sampling at 40th minute yielded fewer false negatives than sampling at 30th or 60th minute.